Diabetes, Sanofi’s Soliqua 100/33 now available in the US

Sanofi announced that Soliqua™ (glargine 100 Units/mL & lixisenatide 33 mcg/mL injection) is available in the US starting from today. The product is intended for the treatment of adults with type 2 diabetes inadequately controlled on basal insulin or lixisenatide. Soliqua 100/33 has demonstrated statistical superiority in terms of glycated hemoglobin level from baseline versus Lantus. The product is available in the SoloStar pen with a dose range covering from 15 to 60 Units. It was granted approval by FDA last November. The daily WAC (Wholesale Acquisition Cost) of Soliqua 100/33 is $127 for a 300 Unit pen, which equals $19.90 per day at the dose of 47 Units used in the trial. (Source Sanofi press release)